NCT04932434CompletedPhase 2
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease
Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease: a Pilot Study
Source: ClinicalTrials.gov · Last updated 3 Sept 2026
Brief summary (registry, in English)
The purpose of this study is to determine the safety, tolerability, and feasibility of psilocybin therapy for depression and anxiety in people with Parkinson's disease.
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 12 (actual)
- First submitted
- 5 May 2021
- Start date
- 15 Aug 2021
- Primary completion date
- 31 Dec 2024
- Lead sponsor
- Joshua Woolley, MD, PhD
- Diseases
- Parkinson disease
- NCT number
- NCT04932434
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 12
- From 15 Aug 2021 to the primary completion date, 31 Dec 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Regular use of medications that may have problematic interactions with psilocybin, including but not limited to dopamine agonists, MAO inhibitors, N-methyl-D-aspartate (NMDAR) antagonists, antipsychotics, and stimulants
Other illness
- Significant cognitive impairment
- A health condition that makes this study unsafe or unfeasible, determined by study physicians
Other
- Psychotic symptoms involving loss of insight
Who the study is looking for
- Age 40 to 75
- Comfortable speaking and writing in English
- Clinically diagnosed early stage Parkinson's Disease (Hoehn and Yahr Stage 1-3 during an "off" period) who meet DSM-5 criteria for a depressive or anxious disorder and meet all other inclusion and exclusion criteria at screening
- Currently experiencing depression and/or anxiety (a formal diagnosis is not necessary)
- Able to attend all in-person visits at UCSF as well as virtual visits
- Have a care partner/support person available throughout the study
- Have an established primary care provider, neurologist, or psychiatrist
Age in the registry: 40 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of California San Francisco Coordinator of this site? Confirm its status | San Francisco | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.